3月21日,腾盛博药(HK02137)发布2024年业绩公告,公司全年未实现收益,实现其他收入1.41亿元,同比减少13.6%,去年亏损额为5.12亿元,同比扩大177.9%。腾盛博药表示,其他收入减少的原因包括:美元等定期存款利率下降导致银行利息收入减少人民币2080万元;政府补助减少。公司亏损额增加主要是因为出现投资相关亏损1.26亿元及减值亏损9030万元。公告显示,腾盛博药正在积极开发其他...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.